Investor Relations

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669.

 

NASDAQ: CMRX

  • NASDAQ: CMRX
  • Apr 29, 2016
  • 4:00 PM ET
  • $5.98
  • 0.00 (0.00%)
  • N/A
Delayed at least 20 minutes.
Refresh quote

SEC Filings

 
Date Filing Description View
Apr 28, 2016 DEFA14A definitive additional proxy materials HTML PDF
Add to Briefcase
Apr 28, 2016 DEF 14A definitive proxy statement HTML PDF XLS Add to Briefcase
Apr 20, 2016 CT ORDER confidential treatment order HTML PDF
Add to Briefcase
Apr 5, 2016 4 mario, ernest HTML PDF XLS Add to Briefcase
Mar 16, 2016 4 mario, ernest HTML PDF XLS Add to Briefcase
Page:
1
... NextLast
= add file to Briefcase

FAQ

 

The Chimerix ticker is CMRX and it is traded on the Nasdaq Global Market.

2505 Meridian Parkway
Suite 100
Durham, NC 27713

You can view our Board of Directors by visiting the Board of Directors section of our Investor Relations website.

You can view our management team by visiting the Management section of our Investor Relations website.

December 31

Chimerix does not expect to declare or pay any cash or other dividends on our common stock.

Chimerix does not currently have a direct stock purchase plan.

Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financial Information portion of our Investor Relations website or directly from the SEC at www.sec.gov.

The transfer agent and registrar for our common stock is:

Computershare Trust Company, N.A.

 

The transfer agent and registrar’s address is:

P.O. Box 43078

Providence, Rhode Island 02940

Please submit your question using the form below.

* Indicates required field